

A Study of the Prevention of Alloimmunisation using Leukocyte-Depleted Red Cell and Platelet Donations

Submission date 19/08/2002	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 19/08/2002	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 11/01/2019	Condition category Cancer	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr - -

Contact details

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

Protocol serial number

LK/FIL

Study information

Scientific Title

A Study of the Prevention of Alloimmunisation using Leukocyte-Depleted Red Cell and Platelet Donations

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Not Specified

Health condition(s) or problem(s) studied

Leukaemia (acute), Leukaemia (chronic)

Interventions

1. Arm A: Patients receive standard non-filtered, non-leukocyte-depleted blood products
2. Arm B: Patients receive Pall filtered blood or platelet donations

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Leukocyte-Depleted Red Cell and Platelet Donations

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

01/04/1992

Eligibility**Key inclusion criteria**

1. Patients with acute leukaemia, chronic myeloid leukaemia, severe aplastic anaemia or high grade lymphoma
2. Patients already known to have Human Leukocyte Antigens (HLA) antibodies or recurrent febrile transfusion reactions are ineligible

3. Any age
4. Fit to undergo the treatments as defined in protocol

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Not Specified

Sex

Not Specified

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1990

Date of final enrolment

01/04/1992

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

UKCCCR Register Co-ordinator

London

United Kingdom

NW1 2DA

Sponsor information

Organisation

Pall Biomedical Ltd (UK)

ROR

<https://ror.org/04hw9y579>

Funder(s)

Funder type

Industry

Funder Name

Pall Biomedical Ltd (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration